Kymera Therapeutics, Inc. (NASDAQ:KYMR) Stake Boosted by Driehaus Capital Management LLC

Driehaus Capital Management LLC lifted its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,390,372 shares of the company's stock after acquiring an additional 61,669 shares during the period. Driehaus Capital Management LLC owned about 2.15% of Kymera Therapeutics worth $55,935,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Blue Trust Inc. increased its stake in Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company's stock valued at $25,000 after buying an additional 270 shares during the period. KBC Group NV lifted its stake in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company's stock valued at $87,000 after purchasing an additional 752 shares during the last quarter. Tower Research Capital LLC TRC boosted its holdings in Kymera Therapeutics by 95.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,812 shares of the company's stock worth $194,000 after purchasing an additional 2,350 shares in the last quarter. Summit Investment Advisors Inc. increased its position in Kymera Therapeutics by 9.0% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company's stock worth $198,000 after buying an additional 406 shares during the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S bought a new position in Kymera Therapeutics during the fourth quarter valued at about $251,000.

Kymera Therapeutics Stock Up 1.9 %

Shares of Kymera Therapeutics stock opened at $29.11 on Thursday. The stock has a market capitalization of $1.90 billion, a P/E ratio of -12.44 and a beta of 2.18. The company has a 50-day simple moving average of $29.57 and a 200 day simple moving average of $37.91. Kymera Therapeutics, Inc. has a 12-month low of $19.45 and a 12-month high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.88) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.12). Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The company had revenue of $7.39 million for the quarter, compared to the consensus estimate of $14.81 million. On average, equities analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Citigroup initiated coverage on Kymera Therapeutics in a report on Thursday, March 13th. They set a "buy" rating and a $52.00 price objective on the stock. HC Wainwright lifted their price target on shares of Kymera Therapeutics from $54.00 to $60.00 and gave the company a "buy" rating in a research report on Friday, February 28th. Finally, Stephens reaffirmed an "overweight" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a report on Tuesday, January 21st. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $56.36.

Insider Activity at Kymera Therapeutics

In other news, COO Jeremy G. Chadwick sold 1,383 shares of the firm's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $42,112.35. Following the sale, the chief operating officer now owns 67,800 shares of the company's stock, valued at $2,064,510. This trade represents a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Bruce N. Jacobs sold 7,035 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $30.45, for a total transaction of $214,215.75. Following the sale, the chief financial officer now owns 201,886 shares in the company, valued at $6,147,428.70. This trade represents a 3.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 10,659 shares of company stock worth $324,567. 15.82% of the stock is currently owned by company insiders.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.